Autolomous selected by Royal Free London NHS Trust to lead digitalization program for cell and gene therapy provision.

London, UK, December 10, 2021 – Autolomous LTD, the market leading developer of critical manufacturing management systems for cell and gene therapies, today announces the Royal Free London NHS Trust‘s Centre for Cell Gene Tissue Therapeutics (CCGTT), UK has selected Autolomous to lead its new cell and gene therapy (CGT) digitalization program.

The digitization program has been designed to orchestrate a seamless digital infrastructure for all CGT operations at the Royal Free London’s Centre for Cell and Gene Tissue Therapeutics. Completion of the initial project will make CCGTT one of the leading sites in the world for digitized CGT infrastructure, and will result in future collaborative expansion. It will play an essential role for the NHS to deliver more cell and gene therapies to more patients.

The digitization program involves the deployment of Autolomous’ AutoloMATE®, its business-critical digital solution designed to increase efficiency, scalability and process streamlining of the GMP manufacturing and product release of cell & gene therapies. The program will also deploy LabVantage’s Laboratory Information Management System (LIMS) and integrate with Ideagens’ Q-Pulse Quality Management System (QMS).

The program is currently planned to last for two years. It will start in the first quarter of 2022, and is scheduled to be completed before the end of 2023. Phase 1 of the project is to deploy Autolomous’ AutoloMATE and LabVantage’s LIMS by the end of 2022. Phase 2 is planned to be completed by the end of the third quarter of 2023, including integrations with Ideagens’ QMS and other installed platforms and existing manufacturing and analytical equipment.

This is the second project for Autolomous concerning digitization of delivery for the UK’s NHS. In July, Autolomous announced it and its partners had received a joint £1 million project grant from UK Research and Innovation (UKRI) to enhance the scheduling and manufacturing of advanced therapies within the UK’s NHS, for the UK’s Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC). As part of the project Autolomous is providing an industry-first demonstration of an electronic Batch Manufacturing Record (eBMR) solution integrating with a dedicated NHS advanced therapies ordering system. This announcement also follows Autolomous’ receipt of a loan from UK Research and Innovation (UKRI) to expedite development of AutoloMATE-Assist, its digital batch verification technology for cell and gene therapies.

“Autolomous is continuing to provide a vital contribution to the UK NHS’s drive to digitize its cell and gene therapy provision to patients within the UK’s healthcare system. It has now been recognized by those responsible for CGT delivery across the UK’s healthcare sector that this is only achievable through a digitized system,” said Alexander Seyf, CEO and Co-founder, Autolomous LTD. “Autolomous is continuing to build a range of partnerships and collaborations in order to achieve this. Whilst these NHS deliveries and integrations are completed, Autolomous will take this UK healthcare provision model and expand this to the US and other major national healthcare networks globally.”

“Implementing a digitalization program is vital to continue the position of CCGTT as a catalyst, at the forefront of the discovery and delivery of cell and gene therapies to patients. The CGT sector is now at the level of complexity where digitalization is essential to deliver, not only, the right therapy to the right patient, but also faster and safer with traceability from start to finish,” said Dr Owen Bain, Co-Director and Head of QC at the Centre for Cell, Gene and Tissue Therapeutics, Royal Free London NHS Foundation Trust. “Developing the digitalization program has involved selecting the best technologies currently available to the market. The combination of these technologies need not only to fulfil their function, but blend seamlessly to operate collectively while in compliance with strict regulatory standards, allowing us to future-proof the facility. It is also really important that the management and support staff in these companies are also able to blend as well as the technology. We selected Autolomous to lead the project for its technology and unrivalled expertise to deliver the technology solutions able to cope with the complexities of the current CGT sector.”

About Autolomous

Autolomous LTD is the market leading developer of critical manufacturing management systems for cell and gene therapies. Autolomous internationally deploys fully integrated, digitized and automated supply chain software solutions. These solutions utilize emerging technologies such as Distributed Ledger Technology (DLT) and Internet of Things (IoT) to ensure compliance with current and future regulatory requirements. As a result, Autolomous enables manufacturers to reduce costs and deliver cell and gene therapies to more patients.

Autolomous’ platform, AutoloMATE® is a business-critical robust digital solution increasing efficiency, scalability and process streamlining of the GMP manufacturing and product release of cell and gene therapies.
Autolomous LTD is headquartered in London. The company was founded in 2019 by four professionals with combined experience covering fifty years in advanced therapies and medical practice and thirty-five years in technology, software and business

Autolomous LTD is headquartered in London. The company was founded in 2019 by four professionals with combined experience covering fifty years in advanced therapies and medical practice and thirty-five years in technology, software and business.